Cilcare
Created in 2014
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
265 4,753Activities
Technologies
Entity types
Location
Rue du Professeur Joseph Anglada, 34090 Montpellier, France
Montpellier
France
Employees
Scale: 11-50
Estimated: 44
SIREN
803146125Engaged corporates
43
13 39Added in Motherbase
5 years, 7 months ago
biotech Value proposition
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
hearing disorders, tinnitus, hearing loss, pharmaceutical development, pharmacology, clinical development, preclinical development, GLP ototoxicology, hearing loss, tinnitus, auditory safety, ear disorders, AI, and precision medicineOriginal language
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
Accueil - Cilcare
https://www.cilcare.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 French Tech Méditerranée French Tech, Software Development | French Tech Méditerranée French Tech, Software Development | Other 7 Apr 2022 4 May 2024 | | |
 BIC de Montpellier Government Administration | BIC de Montpellier Government Administration | Not capitalistic Partnership Event 11 Feb 2021 20 Nov 2024 | | |
 France Invest Startup accelerator & VC, Venture Capital and Private Equity Principals | France Invest Startup accelerator & VC, Venture Capital and Private Equity Principals | Not capitalistic Not partnership Event 11 May 2022 | | |